Video

Dr. Feldman on Remaining Challenges With Biomarkers in Prostate Cancer

Author(s):

Adam Scott Feldman, MD, MPH

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses the remaining challenges with biomarkers in prostate cancer.

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses the remaining challenges with biomarkers in prostate cancer.

There is a plethora of research on biomarkers, but the ones that actually affect clinical care is quite small, says Feldman.

Related Videos
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Chirag Shah, MD
Jason A. Mouabbi, MD
Related Content
Christian Behrenbruch PhD, MBA
July 24th 2024

FDA Accepts the New Drug Application for TLX007-CDx Kit in Prostate Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Razane El Hajj Chehade, MD
July 18th 2024

Clear Cell Histology Associated With Increased Risk of irAEs in Metastatic RCC

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

Christian Rommel, PhD
July 17th 2024

Darolutamide Plus ADT Provides Statistically Significant rPFS Advantage in mHSPC

RCC | Image Credit: © SciePro - stock.adobe.com
July 17th 2024

NCCN Updates Kidney Cancer Clinical Practice Guidelines